Adicet Bio

Adicet Bio is a biotechnology company creating immune cell therapies for treating cancer and other diseases that is headquartered in Menlo park, California and was founded in 2014 by Aya Jakobovitis. 
Funding 
Venture 
﻿On August 26, 2015 Adicet Bio completed a venture capital round raising $14.6 million in funding from undisclosed investors. ﻿
Series A 
﻿﻿On January 27, 2016 Adicet Bio completed their series A funding round with $51 million in funding from OrbiMed (lead investor), Pontifax, and Novartis Venture Fund. ﻿﻿
Acquisitions 
Applied Immune Technologies 
﻿On January 27, 2016 Adicet Bio acquired the Israeli immunotherapy company Applied Immune Technologies. ﻿
﻿

Timeline

October 2019

Adicet Bio raises a $80,000,000 series B round from Novartis Venture Fund, OrbiMed, Pontifax Venture Capital, DSC Investments, aMoon Fund, Johnson & Johnson Innovation – JJDC, Consensus Business Group, Samsung Venture Investment Corporation, Samsung Ventures, KB Investment, Johnson & Johnson Innovation, SBI Japan-Israel Innovation Fund, OCI Enterprises, Handok﻿ and Regeneron Pharmaceuticals.

January 27, 2016

Series A funding round 
﻿﻿On January 27, 2016 Adicet Bio completed their series A funding round with $51 million in funding from OrbiMed (lead investor), Pontifax, and Novartis Venture Fund. ﻿﻿

August 26, 2015

Venture funding round 
﻿On August 26, 2015 Adicet Bio completed a venture capital round raising $14.6 million in funding from undisclosed investors. ﻿

2014